VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | ALLO-715: BCMA allogeneic CAR-T in R/R myeloma

Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares the results of a first-in-human study (NCT04093596) of ALLO-715, an anti-BCMA allogeneic CAR-T cell therapy, in relapsed/refractory (R/R) multiple myeloma. ALLO-715 is genetically modified in the TCR alpha constant gene to reduce graft versus host disease and in the CD52 gene, allowing for prolonged lymphodepletion with ALLO-647, a CD52-targeted monoclonal antibody. Three dose levels of ALLO-715 have been trialed to date, in a standard 3+3 dose-escalation design. A manageable safety profile was observed, with no dose-limiting toxicities, neurotoxicity, or graft versus host disease. Results showed that a higher dose of ALLO-715 was associated with greater efficacy, but CAR T-cell expansion was seen at all dose levels. Enrollment at higher dose levels is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter